[开放获取]    血管性水肿诊疗中国专家共识（2026版）

doi:10.35541/cjd.20250706

Abstract

Abstract: 【Abstract】 Angioedema is a disease characterized by localized swelling of the skin and/or mucosal tissues caused by increased vascular permeability. It encompasses multiple subtypes, some of which are rare, resulting in high rates of missed diagnosis or misdiagnosis in clinical practice. The Chinese Society of Dermatology and the China Dermatologist Association convened a consensus expert panel comprising 31 multidisciplinary experts to propose standardized management and treatment strategies based on evidence-based medicine and clinical practice experience. This consensus also emphasizes the importance of patient education and multidisciplinary treatment, with the aim of deepening clinicians' understanding of angioedema, enhancing standardized diagnosis and treatment, and ultimately improving the quality of life of patients with angioedema.

Key words: Angioedema, Mast cells, Bradykinin, C1 esterase inhibitor, Expert consensus

Chinese Society of Dermatology, China Dermatologist Association. Chinese expert consensus on the diagnosis and treatment of angioedema （2026 edition）[J]. Chinese Journal of Dermatology,2026,e20250706. doi:10.35541/cjd.20250706

References ［65］

［1］	Maurer M, Magerl M, Betschel S, et al. The International WAO/EAACI guideline for the management of hereditary angioedema⁃the 2021 revision and update［J］. Allergy, 2022,77（7）:1961⁃1990. DOI: 10.1111/all.15214.
［2］	国家卫生健康委员会. 关于公布第一批罕见病目录的通知［EB/OL］. （2018⁃05⁃11）［2026⁃07⁃07］. http://www.nhc.gov.cn/yzygj/s7659/201806/393a9a37f39c4b458d6e830f40a4bb99.shtml.
［3］	Madsen F, Attermann J, Linneberg A. Epidemiology of non⁃hereditary angioedema［J］. Acta Derm Venereol, 2012,92（5）:475⁃479. DOI: 10.2340/00015555⁃1389.
［4］	Sánchez⁃Borges M, Ansotegui IJ, Baiardini I, et al. The challenges of chronic urticaria part 1: epidemiology, immunopathogenesis, comorbidities, quality of life, and management［J］. World Allergy Organ J, 2021,14（6）:100533. DOI: 10.1016/j.waojou.2021.100533.
［5］	Li J, Mao D, Liu S, et al. Epidemiology of urticaria in China: a population⁃based study［J］. Chin Med J （Engl）, 2022,135（11）:1369⁃1375. DOI: 10.1097/CM9.0000000000002172.
［6］	Ng JY, Ooi M, Bennett SK, et al. Acquired angioedema associated with lymphoproliferative disorders［J］. Case Rep Oncol, 2024,17（1）:329⁃336. DOI: 10.1159/000536458.
［7］	Garcia⁃Saucedo JC, Trejo⁃Gutierrez JF, Volcheck GW, et al. Incidence and risk factors of angiotensin⁃converting enzyme inhibitor⁃induced angioedema: a large case⁃control study［J］. Ann Allergy Asthma Immunol, 2021,127（5）:591⁃592. DOI: 10. 1016/j.anai.2021.07.028.
［8］	Guan X, Sheng Y, Liu S, et al. Epidemiology, economic, and humanistic burden of hereditary angioedema: a systematic review［J］. Orphanet J Rare Dis, 2024,19（1）:256. DOI: 10.1186/s13023⁃024⁃03265⁃z.
［9］	Reshef A, Buttgereit T, Betschel SD, et al. Definition, acronyms, nomenclature, and classification of angioedema （DANCE）: AAAAI, ACAAI, ACARE, and APAAACI DANCE consensus［J］. J Allergy Clin Immunol, 2024,154（2）:398⁃411. DOI: 10. 1016/j.jaci.2024.03.024.
［10］	Lang DM, Sheikh J, Joshi S, et al. Endotypes, phenotypes, and biomarkers in chronic spontaneous urticaria: evolving toward personalized medicine［J］. Ann Allergy Asthma Immunol, 2025,134（4）:408⁃417. DOI: 10.1016/j.anai.2024.10.026.
［11］	Puxeddu I, Pistone F, Pisani F, et al. Mast cell signaling and its role in urticaria［J］. Ann Allergy Asthma Immunol, 2024,133（4）:374⁃379. DOI: 10.1016/j.anai.2024.04.023.
［12］	中华医学会皮肤性病学分会荨麻疹研究中心. 中国荨麻疹诊疗指南（2022版）［J］. 中华皮肤科杂志, 2022,55（12）:1041⁃1049. DOI: 10.35541/cjd.20220609.
［13］	谢苗苗, 朱小飞. 慢性自发性荨麻疹发病机制的研究进展［J］. 免疫学杂志, 2023, 39（4）:354⁃360.
［14］	Betschel S, Badiou J, Binkley K, et al. The International/Canadian hereditary angioedema guideline［J］. Allergy Asthma Clin Immunol, 2019,15:72. DOI: 10.1186/s13223⁃019⁃0376⁃8.
［15］	Sharma J, Jindal AK, Banday AZ, et al. Pathophysiology of hereditary angioedema （HAE） beyond the SERPING1 gene［J］. Clin Rev Allergy Immunol, 2021,60（3）:305⁃315. DOI: 10.1007/s12016⁃021⁃08835⁃8.
［16］	Zuraw BL, Bork K, Bouillet L, et al. Hereditary angioedema with normal C1 inhibitor: an updated international consensus paper on diagnosis, pathophysiology, and treatment［J］. Clin Rev Allergy Immunol, 2025,68（1）:24. DOI: 10.1007/s12016⁃025⁃09027⁃4.
［17］	Castelli R, Zanichelli A, Cicardi M, et al. Acquired C1⁃inhibitor deficiency and lymphoproliferative disorders: a tight relationship［J］. Crit Rev Oncol Hematol, 2013,87（3）:323⁃332. DOI: 10. 1016/j.critrevonc.2013.02.004.
［18］	Lacuesta G, Betschel SD, Tsai E, et al. Angioedema［J］. Allergy Asthma Clin Immunol, 2024,20（Suppl 3）:65. DOI: 10.1186/s13223⁃024⁃00934⁃3.
［19］	Mathey CM, Maj C, Scheer AB, et al. Molecular genetic screening in patients with ACE inhibitor/angiotensin receptor blocker⁃induced angioedema to explore the role of hereditary angioedema genes［J］. Front Genet, 2022,13:914376. DOI: 10. 3389/fgene.2022.914376.
［20］	Maurer M, Magerl M. Differences and similarities in the mechanisms and clinical expression of bradykinin⁃mediated vs. mast cell⁃mediated angioedema［J］. Clin Rev Allergy Immunol, 2021,61（1）:40⁃49. DOI: 10.1007/s12016⁃021⁃08841⁃w.
［21］	Balla Z, Andrási N, Pólai Z, et al. The characteristics of upper airway edema in hereditary and acquired angioedema with C1⁃inhibitor deficiency［J］. Clin Transl Allergy, 2021,11（10）:e12083. DOI: 10.1002/clt2.12083.
［22］	Obtułowicz P, Stobiecki M, Dyga W, et al. Abdominal and pelvic imaging in the diagnosis of acute abdominal attacks in patients with hereditary angioedema due to C1⁃inhibitor deficiency［J］. Postepy Dermatol Alergol, 2022,39（4）:749⁃756. DOI: 10.5114/ada.2021.108438.
［23］	Caballero T, Maurer M, Longhurst HJ, et al. Triggers and prodromal symptoms of angioedema attacks in patients with hereditary angioedema［J］. J Investig Allergol Clin Immunol, 2016,26（6）:383⁃386. DOI: 10.18176/jiaci.0102.
［24］	Maia L, Moreno AS, Ferriani M, et al. Genotype⁃phenotype correlations in Brazilian patients with hereditary angioedema due to C1 inhibitor deficiency［J］. Allergy, 2019,74（5）:1013⁃1016. DOI: 10.1111/all.13699.
［25］	Montinaro V, Cicardi M. ACE inhibitor⁃mediated angioedema［J］. Int Immunopharmacol, 2020,78:106081. DOI: 10.1016/j.intimp.2019.106081.
［26］	中华医学会皮肤性病学分会荨麻疹研究中心. 中国荨麻疹诊疗指南（2018版）［J］. 中华皮肤科杂志, 2019,52（1）:1⁃5. DOI: 10.3760/cma.j.issn.0412⁃4030.2019.01.001.
［27］	Tarzi MD, Hickey A, Förster T, et al. An evaluation of tests used for the diagnosis and monitoring of C1 inhibitor deficiency: normal serum C4 does not exclude hereditary angioedema［J］. Clin Exp Immunol, 2007,149（3）:513⁃516. DOI: 10.1111/j.1365⁃2249.2007.03438.x.
［28］	Busse PJ, Christiansen SC, Riedl MA, et al. US HAEA medical advisory board 2020 guidelines for the management of hereditary angioedema［J］. J Allergy Clin Immunol Pract, 2021,9（1）:132⁃150.e3. DOI: 10.1016/j.jaip.2020.08.046.
［29］	Zanichelli A, Arcoleo F, Barca MP, et al. A nationwide survey of hereditary angioedema due to C1 inhibitor deficiency in Italy［J］. Orphanet J Rare Dis, 2015,10:11. DOI: 10.1186/s13023⁃015⁃0233⁃x.
［30］	Gil⁃Serrano J, Labrador⁃Horrillo M, Galvan⁃Blasco P, et al. Systemic inflammation biomarkers during angioedema attacks in hereditary angioedema［J］. Front Immunol, 2024,15:1400526. DOI: 10.3389/fimmu.2024.1400526.
［31］	遗传性血管性水肿消化科诊疗协作组. 遗传性血管性水肿消化科诊疗路径［J］. 中华消化杂志, 2024,44（5）:289⁃295. DOI: 10.3760/cma.j.cn311367⁃20240229⁃00078.
［32］	周宁, 韩小彤, 陈松, 等. 遗传性血管性水肿急诊科诊疗路径［J］. 中国急救医学, 2024,44（2）:99⁃105. DOI: 10.3969/j.issn. 1002⁃1949.2024.02.002.
［33］	Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international EAACI/GA²LEN/Euroguiderm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria［J］. Allergy, 2022,77（3）:734⁃766. DOI: 10.1111/all. 15090.
［34］	Can PK, Degi Rmentepe EN, Etikan P, et al. Assessment of disease activity and quality of life in patients with recurrent bradykinin⁃mediated versus mast cell⁃mediated angioedema［J］. World Allergy Organ J, 2021,14（7）:100554. DOI: 10.1016/j.waojou.2021.100554.
［35］	Weller K, Donoso T, Magerl M, et al. Validation of the Angioedema Control Test （AECT）⁃a patient⁃reported outcome instrument for assessing angioedema control［J］. J Allergy Clin Immunol Pract, 2020,8（6）:2050⁃2057.e4. DOI: 10.1016/j.jaip. 2020.02.038.
［36］	Mak H, Wong J, So S, et al. Validation and correlations of the Angioedema Activity Score （AAS）, Angioedema Quality of Life （AE⁃QoL） questionnaire, and Angioedema Control Test （AECT） in Chinese patients with angioedema［J］. J Allergy Clin Immunol Glob, 2024,3（4）:100295. DOI: 10.1016/j.jacig.2024. 100295.
［37］	Chaichan W, Ruengorn C, Thavorn K, et al. Comparative safety profiles of individual second⁃generation H1⁃antihistamines for the treatment of chronic urticaria: a systematic review and network meta⁃analysis of randomized controlled trials［J］. J Allergy Clin Immunol Pract, 2023,11（8）:2365⁃2381. DOI: 10. 1016/j.jaip.2023.03.058.
［38］	Zhang L, Wu J, Qi Y, et al. Long⁃term combinations and updosing of second⁃generation H1⁃antihistamines show efficacy and safety in the treatment of chronic spontaneous urticaria: a multicenter real⁃life pilot study［J］. J Allergy Clin Immunol Pract, 2020,8（5）:1733⁃1736. DOI: 10.1016/j.jaip.2019. 12.006.
［39］	Iriarte Sotés P, Armisén M, Usero⁃Bárcena T, et al. Efficacy and safety of up⁃dosing antihistamines in chronic spontaneous urticaria: a systematic review of the literature［J］. J Investig Allergol Clin Immunol, 2021,31（4）:282⁃291. DOI: 10.18176/jiaci.0649.
［40］	Zhao ZT, Ji CM, Yu WJ, et al. Omalizumab for the treatment of chronic spontaneous urticaria: a meta⁃analysis of randomized clinical trials［J］. J Allergy Clin Immunol, 2016,137（6）:1742⁃1750. DOI: 10.1016/j.jaci.2015.12.1342.
［41］	Kulthanan K, Chaweekulrat P, Komoltri C, et al. Cyclosporine for chronic spontaneous urticaria: a meta⁃analysis and systematic review［J］. J Allergy Clin Immunol Pract, 2018,6（2）:586⁃599. DOI: 10.1016/j.jaip.2017.07.017.
［42］	Hide M, Staubach P, Khemis A, et al. Remibrutinib demonstrates sustained control of angioedema in patients with chronic spontaneous urticaria: 52⁃week treatment results from the phase 3 REMIX studies［C］//EAACI 2025, 2025.
［43］	Ding L, Zhang MJ, Rao GW. Summary and future of medicine for hereditary angioedema［J］. Drug Discov Today, 2024,29（3）:103890. DOI: 10.1016/j.drudis.2024.103890.
［44］	Nicola S, Rolla G, Brussino L. Breakthroughs in hereditary angioedema management: a systematic review of approved drugs and those under research［J］. Drugs Context, 2019,8:212605. DOI: 10.7573/dic.212605.
［45］	Uminski K, Goodyear D, Betschel S. Therapeutic advances in hereditary angioedema: a focus on present and future options［J］. Adv Ther, 2025,42（12）:5879⁃5895. DOI: 10.1007/s12325⁃025⁃03382⁃6.
［46］	Craig TJ, Bewtra AK, Bahna SL, et al. C1 esterase inhibitor concentrate in 1085 hereditary angioedema attacks⁃⁃final results of the I.M.P.A.C.T.2 study［J］. Allergy, 2011,66（12）:1604⁃1611. DOI: 10.1111/j.1398⁃9995.2011.02702.x.
［47］	Zuraw B, Cicardi M, Levy RJ, et al. Recombinant human C1⁃inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema［J］. J Allergy Clin Immunol, 2010,126（4）:821⁃827. DOI: 10.1016/j.jaci.2010.07.021.
［48］	Rosi⁃Schumacher M, Shah SJ, Craig T, et al. Clinical manifestations of hereditary angioedema and a systematic review of treatment options［J］. Laryngoscope Investig Otolaryngol, 2021,6（3）:394⁃403. DOI: 10.1002/lio2.555.
［49］	Wentzel N, Panieri A, Ayazi M, et al. Fresh frozen plasma for on⁃demand hereditary angioedema treatment in south africa and iran［J］. World Allergy Organ J, 2019,12（9）:100049. DOI: 10.1016/j.waojou.2019.100049.
［50］	Farkas H, Zotter Z, Csuka D, et al. Short⁃term prophylaxis in hereditary angioedema due to deficiency of the C1⁃inhibitor⁃⁃a long⁃term survey［J］. Allergy, 2012,67（12）:1586⁃1593. DOI: 10.1111/all.12032.
［51］	中国医师协会变态反应医师分会, 中华医学会变态反应学分会, 中国罕见病联盟北京罕见病诊疗与保障学会变态反应学分会, 等. 中国遗传性血管性水肿诊断与治疗专家共识（2024版）［J］. 中华临床免疫和变态反应杂志, 2025,19（1）:1⁃10. DOI: 10.3969/j.issn.1673⁃8705.2025.01.001.
［52］	Prematta M, Gibbs JG, Pratt EL, et al. Fresh frozen plasma for the treatment of hereditary angioedema［J］. Ann Allergy Asthma Immunol, 2007,98（4）:383⁃388. DOI: 10.1016/S1081⁃1206（10）60886⁃1.
［53］	Beard N, Frese M, Smertina E, et al. Interventions for the long⁃term prevention of hereditary angioedema attacks［J］. Cochrane Database Syst Rev, 2022,11:CD013403. DOI: 10.1002/14651858. CD013403.pub2.
［54］	Betschel S, Badiou J, Binkley K, et al. Correction to: the International/Canadian hereditary angioedema guideline［J］. Allergy Asthma Clin Immunol, 2020,16:33. DOI: 10.1186/s13223⁃ 020⁃00430⁃4.
［55］	Xu Y, Zhi Y. Long⁃term prophylaxis of hereditary angioedema with danazol［J］. Chin Med J （Engl）, 2022,135（21）:2642⁃2643. DOI: 10.1097/CM9.0000000000002144.
［56］	Horiuchi T, Hide M, Yamashita K, et al. The use of tranexamic acid for on⁃demand and prophylactic treatment of hereditary angioedema: a systematic review［J］. J Cutan Immunol Allergy, 2018,1:126⁃138. DOI: 10.1002/cia2.12029.
［57］	Zingale LC, Castelli R, Zanichelli A, et al. Acquired deficiency of the inhibitor of the first complement component: presentation, diagnosis, course, and conventional management［J］. Immunol Allergy Clin North Am, 2006,26（4）:669⁃690. DOI: 10.1016/j.iac.2006.08.002.
［58］	Longhurst HJ, Zanichelli A, Caballero T, et al. Comparing acquired angioedema with hereditary angioedema （types i/ii）: findings from the icatibant outcome survey［J］. Clin Exp Immunol, 2017,188（1）:148⁃153. DOI: 10.1111/cei.12910.
［59］	Xiao X, Xue P, Shi Y, et al. The efficacy and safety of high⁃dose nonsedating antihistamines in chronic spontaneous urticaria: a systematic review and meta⁃analysis of randomized clinical trials［J］. BMC Pharmacol Toxicol, 2023,24（1）:23. DOI: 10.1186/s40360⁃023⁃00665⁃y.
［60］	Song XT, Chen YD, Yu M, et al. Omalizumab in children and adolescents with chronic urticaria: a 16⁃week real⁃world study［J］. Allergy, 2021,76（4）:1271⁃1273. DOI: 10.1111/all.14686.
［61］	Nettis E, Cegolon L, Di Leo E, et al. Omalizumab in elderly patients with chronic spontaneous urticaria: an Italian real⁃life experience［J］. Ann Allergy Asthma Immunol, 2018,120（3）:318⁃323. DOI: 10.1016/j.anai.2017.12.007.
［62］	Levi⁃Schaffer F, Mankuta D. Omalizumab safety in pregnancy［J］. J Allergy Clin Immunol, 2020,145（2）:481⁃483. DOI: 10. 1016/j.jaci.2019.11.018.
［63］	González⁃Quevedo T, Larco JI, Marcos C, et al. Management of pregnancy and delivery in patients with hereditary angioedema due to C1 inhibitor deficiency［J］. J Investig Allergol Clin Immunol, 2016,26（3）:161⁃167. DOI: 10.18176/jiaci.0037.
［64］	Norris M, Ashoor Z, Craig T. Management of pediatric hereditary angioedema types 1 and 2: a search for international consensus［J］. Allergy Asthma Proc, 2022,43（5）:388⁃396. DOI: 10.2500/aap.2022.43.220052.
［65］	贾薇, 索利敏, 范林静, 等. 一个遗传性血管性水肿家系的临床及基因研究［J］. 中华耳鼻咽喉头颈外科杂志, 2022,57（8）:980⁃985. DOI: 10.3760/cma.j.cn115330⁃20211209⁃00789.

[1]	China Dermatologist Association, Chinese Society of Dermatology, Dermatology Branch of China International Exchange and Promotive Association for Medical and Health Care, Dermatology Branch of China Alliance for Rare Diseases. Expert consensus on the long-term management of plaque psoriasis with biologic agents （2026 edition） [J]. Chinese Journal of Dermatology, 2026, 59(9): 827-843.
[2]	Gao Haiqing, Ma Li, Yang Fanping, Chen Sheng'an, Zhao Ying, Luo Xiaoqun. Clinical and genetic characteristics of 36 patients with hereditary angioedema [J]. Chinese Journal of Dermatology, 2026, 59(9): 881-887.
[3]	Expert Group on the “Chinese expert consensus on sirolimus in the treatment of Kaposiform hemangioendothelioma （ edition）”. Chinese expert consensus on sirolimus in the treatment of Kaposiform hemangioendothelioma （2026 edition） [J]. Chinese Journal of Dermatology, 2026, 59(8): 728-737.
[4]	Writing Committee Expert Group on “Diagnosis and treatment of pustular psoriasis: a Chinese expert consensus statement （ edition）”. Diagnosis and treatment of pustular psoriasis: a Chinese expert consensus statement （2026 edition） [J]. Chinese Journal of Dermatology, 2026, 59(8): 717-727.
[5]	Hair Disease Rehabilitation Group, Chinese Association of Rehabilitation Dermatology, Hair Medicine Branch, Beijing Association of Holistic Integrative Medicine, Hair Research Group, Chinese Society of Dermatology, National Clinical Research Center for Dermatologic and Immunologic Diseases. Chinese expert consensus on hair biopsy and pathology （2026 edition） [J]. Chinese Journal of Dermatology, 2026, 59(5): 419-426.
[6]	Chinese Society of Dermatology, China Dermatologist Association, Dermatology Branch of China International Exchange and Promotive Association for Medical and Health Care, Dermatology Branch of China Alliance for Rare Diseases. Expert consensus on fecal microbiota transplantation in the treatment of psoriasis （2026 edition） [J]. Chinese Journal of Dermatology, 2026, 59(5): 427-435.
[7]	Blistering Diseases Research Group, China “Belt and Road” Dermatology Alliance, Collaborative Group on Pemphigus/Bullous Pemphigoid Research, Chinese Society of Dermatology. Expert consensus on the diagnosis and treatment of anti-p200 pemphigoid （2026 edition） [J]. Chinese Journal of Dermatology, 2026, 59(5): 387-395.
[8]	Pediatric Dermatology Group, Professional Committee of Pediatric Allergy, China Maternal and Child Health Association. Chinese expert consensus on the diagnosis and management of pediatric anogenital lichen sclerosus （2026 edition） [J]. Chinese Journal of Dermatology, 2026, 59(5): 396-406.
[9]	Society of Aesthetic Dermatology, Chinese Association of Plastics and Aesthetics, Dermatology Committee, Chinese Non-government Medical Institutions Association. Expert recommendations on the application of medical recombinant humanized collagens in facial rejuvenation （2026 edition） [J]. Chinese Journal of Dermatology, 2026, 59(4): 320-326.
[10]	Group on Children, Chinese Society of Dermatology, Pediatric Dermatology Group, Chinese Association of Rehabilitation Dermatology, Pediatric Dermatology Group, China Dermatologist Association, External Therapy Group, Professional Committee for Children's Health and Drug Research, China Association of Traditional Chinese Medicine, Dermatology Group, China Pediatrician Association. Expert consensus on the diagnosis and treatment of pediatric alopecia areata in China （2026 edition） [J]. Chinese Journal of Dermatology, 2026, 59(4): 291-303.
[11]	Committee on Skin Disease and Cosmetic Dermatology, China Association of Medical Equipment, Patient Education Expert Committee, Chinese Society of Clinical Oncology . Chinese expert consensus on multidisciplinary management of cancer treatment-related cutaneous adverse events （2026 edition） [J]. Chinese Journal of Dermatology, 2026, 59(4): 304-319.
[12]	Committee on Psoriasis, Chinese Society of Dermatology. Expert consensus on management of psoriasis with comorbidities （2026） [J]. Chinese Journal of Dermatology, 2026, 59(3): 193-207.
[13]	Expert Group on the Interpretation of the "Chinese expert consensus on the clinical application of photobiomodulation therapy in dermatology （）", Laser Medicine Group, Chinese Society of Dermatology. Interpretation of the Chinese expert consensus on the clinical application of photobiomodulation therapy in dermatology （2025） [J]. Chinese Journal of Dermatology, 2026, 59(3): 208-212.
[14]	Liu Jia, Gu Yinghua, He Xiaoning, . Treatment and disease burden of hereditary angioedema [J]. Chinese Journal of Dermatology, 2026, 59(3): 282-286.
[15]	Chinese Society of Dermatology, China Dermatologist Association, Dermatology Branch of China International Exchange and Promotive Association for Medical and Health Care, Rare Skin Diseases Committee, China Alliance for Rare Diseases. Expert consensus on spesolimab in the treatment of inflammatory skin diseases （2026 edition） [J]. Chinese Journal of Dermatology, 2026, 59(2): 113-119.

Chinese expert consensus on the diagnosis and treatment of angioedema （2026 edition）

PDF

PDF (Mobile)

Knowledge

Abstract

Cite this article

share this article

References ［65］

Related Articles 15

Metrics

Comments

Recommended 10